Mizuho analyst Salim Syed raised the firm’s price target on Assembly Biosciences (ASMB) to $40 from $29 and keeps an Outperform rating on the shares. The firm updated the company’s model to reflect the recent positive ABI-5366 data.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASMB:
- Assembly Biosciences: Strong Clinical Execution and Strategic Partnerships Drive Buy Rating
- Assembly Biosciences Inc. Reports Q3 2025 Earnings
- Assembly Biosciences reports Q3 EPS (72c), consensus (65c)
- Assembly Biosciences announces Phase 1b data for ABI-4334
- ASMB Earnings this Week: How Will it Perform?